NPS Pharma maintained by Jefferies at buy

NPS Pharmaceuticals Inc. was maintained by Jefferies & Co. analyst Adam Walsh at a buy rating with a price target on the stock of $16 per share after second-quarter earnings. Jefferies believes there are nice long-term prospects for its osteoporosis drug Preos, an advancing pipeline of other drugs and an attractive valuation on the stock. NPS shares Wednesday dropped $0.50, or 4.46%, to close at $10.70 on volume of 978,402 shares versus the three-month running average of 409,482 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.